Stock Financial Ratios, Dividends, Split History

PHH / PHH Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price10.85
Volume93,700.00
Market Cap ($M)352.60
Enterprise Value ($M)-127.40
Book Value ($M)523.00
Book Value / Share16.06
Price / Book0.67
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Stock Shares Outstanding 32,547,258
Preferred Stock Shares Outstanding 0
Common Shares Outstanding 32,551,759
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.35
Return on Assets (ROA)-0.06
Return on Equity (ROE)-0.18
Balance Sheet (mrq) ($M)
Assets1,513.00
Liabilities990.00
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Disposal Group Including Discontinued Operation Revenue0.00
Revenues456,000,000.00
Net Income-194.00
Earnings Per Share Basic And Diluted-4.62
Cash Flow Statement (mra) ($M)
Cash From Operations303.00
Cash from Investing197.00
Cash from Financing197.00
Identifiers and Descriptors
CUSIP693320202
Central Index Key (CIK)77776
Related CUSIPS
693320902 693320952 069332020

Split History

Stock splits are used by PHH Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

4h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

5h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

How Trump's Supreme Court nominee ruled on hot-button issues | Euronews

2018-07-11 euronews
Supreme Court nominee Judge Brett Kavanaugh has written almost 300 opinions on a range of issues over his 12 years serving on the federal appellate court. In a piece for SCOTUSblog, Edith Roberts noted that, "Kavanaugh generally brings a pragmatic approach to judging, although his judicial philosophy is conservative, and he has applied principles of textualism and originalism espoused by the late Justice Antonin Scalia.

Stocks making the biggest moves premarket: GE, LEN, FDS, HOG, VALE & more

2018-06-26 cnbc
General Electric – GE announced plans to spin off its health-care unit, selling 20 percent and distributing the rest to shareholders, and it will also exit its stake in Baker Hughes over the next two to three years. Today is also the first time since 1907 that the Dow Jones Industrial Average will trade without GE as a member, with the stock replaced in the Dow by Walgreens Boots Alliance. (96-0)

CFPB's Mulvaney set to drop PHH case | American Banker

2018-06-06 americanbanker
The Consumer Financial Protection Bureau is poised to dismiss its case against PHH Corp., a nonbank mortgage lender and servicer whose appeal of a $109 million penalty led to a four-year legal battle over whether the agency's single-director structure was constitutional. (1-0)

Ocwen (OCN) Stock Up 5.1% on Q1 Earnings Beat, Costs Down

2018-05-03 zacks
Shares of Ocwen Financial Corporation (OCN - Free Report) gained nearly 5.1% following the release of first-quarter 2018 results. Earnings were 2 cents per share while the Zacks Consensus Estimate was a loss of 33 cents. Also, the figure reflected improvement from the prior-year quarter’s loss of 26 cents. Results primarily benefited from a decrease in expenses, which resulted from the company’s efforts to sell Mortgage Servicing Rights (MSR) and trim operations to focus on the core business. (11-0)

Ocwen Financial's (OCN) CEO Ronald Faris on Q1 2018 Results - Earnings Call Transcript

2018-05-02 seekingalpha
Good day, ladies and gentlemen, and welcome to the Ocwen Financial’s First Quarter 2018 Earnings Call. At this time, all participants are in listen-only mode. Later we will conduct a question-and-answer session, and instructions will follow at that time. [Operator Instructions] As a reminder, this call may be recorded. I would now like to introduce your host for today’s conference, Mr. Stephen Swett. (75-0)

CUSIP: 693320202